Research programme: myeloid targeting LNPS - ME Therapeutics
Alternative Names: myeloid targeting lipid nanoparticles - ME TherapeuticsLatest Information Update: 25 Jan 2024
At a glance
- Originator ME Therapeutics
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 16 Jan 2024 Early research in Cancer in Canada (unspecified route) prior to January 2024 (ME Therapeutics pipeline, January 2024)